Chronic Lymphocytic Leukemia

Decade-long trial shows continuous ibrutinib delivers durable survival in high-risk or older CLL, with emerging uMRD and manageable cardiac risks.

UK trial data show TP53 and unmutated IGHV outperform copy-number complexity for CLL prognosis, guiding smarter molecular risk stratification.

During a live event, Catherine Coombs, MD and participants explored fixed-duration frontline CLL therapies, focusing on patient selection, data gaps, and trade-offs.

During a live event, Catherine Coombs, MD and participants debate frontline CLL BTK inhibitors: who benefits from continuous therapy, acalabrutinib vs zanubrutinib nuances, and pirtobrutinib's future role.

Interim phase 1b results show off-the-shelf CD19 CAR T azer-cel drives high response rates in hard-to-treat CLL/SLL and MZL.

Modeling shows zanubrutinib may cut progression and costs versus acalabrutinib in relapsed/refractory CLL, especially in high-risk patients.

Cross-trial analysis shows zanubrutinib delivers longer progression-free survival than ibrutinib or acalabrutinib in relapsed CLL, including high-risk del(17p)/del(11q).

FDA approves 14‑month, all‑oral acalabrutinib plus venetoclax first-line for CLL/SLL, boosting progression-free survival and offering a fixed-duration alternative to chemo.

During a live event, Andrew H. Lipsky, MD, and participants weigh acalabrutinib, zanubrutinib and pirtobrutinib, comparing real-world side effects, cardiac risks, and dosing tradeoffs.

During a live event, Andrew H. Lipsky, MD, and participants discuss emerging trial data and real-world applications of innovative CLL treatment combinations.

A new study reveals that combining ianalumab with ibrutinib offers promising results for chronic lymphocytic leukemia, enabling some patients to stop therapy.

New genomic insights reveal how pirtobrutinib effectively targets resistance in relapsed CLL, reshaping treatment strategies for better outcomes.

New data from the SEQUOIA trial highlights the effectiveness of zanubrutinib and venetoclax in achieving high progression-free survival rates in CLL/SLL patients.

Pirtobrutinib shows significant improvement in progression-free survival for untreated CLL/SLL, potentially setting a new standard of care.

Pirtobrutinib demonstrates an impressive 81.6% response rate in CLL/SLL patients previously treated with BTK inhibitors, showcasing its efficacy and safety.

Zanubrutinib shows sustained efficacy and safety in relapsed/refractory CLL, with a median progression-free survival of 52.5 months in long-term follow-up.

Pirtobrutinib shows superior overall response rates and promising progression-free survival compared to ibrutinib in treating chronic lymphocytic leukemia.

Lisaftoclax shows promising efficacy and safety in treating relapsed/refractory CLL/SLL, achieving a 62.5% response rate and 23.89 months progression-free survival.

Pirtobrutinib receives FDA traditional approval for relapsed CLL, showing significant progression-free survival benefits in clinical trials.

Recent study results confirm that the venetoclax and obinutuzumab combination is a cost-effective treatment for patients with chronic lymphocytic leukemia in Canada.

A phase 2 study reveals high efficacy and manageable safety of venetoclax plus obinutuzumab for untreated CLL/SLL in Japanese patients.

At the 43rd Annual CFS meeting, John Allan, MD, highlighted ongoing efforts to advance the treatment paradigm for chronic lymphocytic leukemia.

During a live event, Mazyar Shadman, MD, MPH, discussed zanubrutinib’s long-term outcomes in CLL for high-risk patients.